Christina Marie Charles-Schoeman

Title(s)Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Mechanisms Linking Joint Inflammation and Atherosclerosis in Rheumatoid Arthritis
    NIH R01HL123064Nov 15, 2014 - Oct 31, 2020
    Role: Principal Investigator
    Does Aggressive Treatment in Early RA Reduce Biomarkers of Cardiovascular Risk?
    NIH R21AR057913Jul 1, 2010 - May 31, 2013
    Role: Principal Investigator
    HDL Function as a Biomarker for Atherosclerotic Risk in Rheumatoid Arthritis
    NIH K23HL094834Sep 1, 2009 - May 31, 2015
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open. 2024 Apr 12; 10(2). Buch MH, Bhatt DL, Charles-Schoeman C, Giles JT, Mikuls T, Koch GG, Ytterberg S, Nagy E, Jo H, Kwok K, Connell CA, Masri KR, Yndestad A. PMID: 38609322.
      View in: PubMed   Mentions:
    2. Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-enriched Rheumatoid Arthritis Patients. Arthritis Rheumatol. 2024 Mar 13. Charles-Schoeman C, Fleischmann R, Mysler E, Greenwald M, Ytterberg SR, Koch GG, Bhatt DL, Wang C, Mikuls TR, Chen AS, Connell CA, Woolcott JC, Menon S, Chen Y, Lee K, Szekanecz Z. PMID: 38481002.
      View in: PubMed   Mentions:    Fields:    
    3. Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024 Mar; 20(3):196. Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, Ytterberg SR, Hamar A, Fleischmann R. PMID: 38302658.
      View in: PubMed   Mentions:    Fields:    
    4. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 01 17; 26(1):27. Aggarwal R, Schessl J, Charles-Schoeman C, Bata-Csörgo Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Beckmann I, Clodi E, Levine T, ProDERM investigators. PMID: 38233885; PMCID: PMC10792872.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024 Feb; 20(2):101-115. Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, Ytterberg SR, Hamar A, Fleischmann R. PMID: 38216757.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatol Ther. 2024 Feb; 11(1):157-175. Charles-Schoeman C, Giles JT, Lane NE, Choy E, Furst DE, Vencovský J, Wilson AG, Burmester GR, Coombs D, Penn SK, Khan N, Yee JB, Rahawi K, McInnes IB. PMID: 38180720; PMCID: PMC10796877.
      View in: PubMed   Mentions:
    7. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 11; 9(4). Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. PMID: 37945286; PMCID: PMC10649869.
      View in: PubMed   Mentions: Translation:Humans
    8. Correction to: Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis. Clin Rheumatol. 2023 Nov; 42(11):3175. Razmjou AA, Wang JM, Shahbazian A, Reddy S, Charles-Schoeman C. PMID: 37707640; PMCID: PMC10587016.
      View in: PubMed   Mentions:    Fields:    
    9. Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study. EClinicalMedicine. 2023 Oct; 64:102234. Werth VP, Aggarwal R, Charles-Schoeman C, Schessl J, Levine T, Kopasz N, Worm M, Bata-Csörgo Z. PMID: 37799613; PMCID: PMC10550512.
      View in: PubMed   Mentions:
    10. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15. Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. PMID: 37453736.
      View in: PubMed   Mentions:    Fields:    
    11. Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies receiving treatment with intravenous immunoglobulin. Rheumatol Int. 2023 09; 43(9):1629-1636. Bae SS, Faure-Kumar E, Ferbas K, Wang J, Shahbazian A, Truong L, Yang H, McMahon M, FitzGerald JD, Charles-Schoeman C. PMID: 37368037; PMCID: PMC10348966.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    12. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 09; 82(9):1130-1141. Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. PMID: 37308218; PMCID: PMC10423494.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    13. Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis. Rheumatol Int. 2023 06; 43(6):1041-1053. Charles-Schoeman C, Wang J, Shahbazian A, Wilhalme H, Brook J, Kaeley GS, Oganesian B, Ben-Artzi A, Elashoff DA, Ranganath VK. PMID: 36828925; PMCID: PMC10125943.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 04; 82(4):575-577. Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Connell CA, Yndestad A, Rivas JL, Buch MH. PMID: 36720582; PMCID: PMC10086292.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    15. Trial of Intravenous Immune Globulin in Dermatomyositis. Reply. N Engl J Med. 2023 01 05; 388(1):94-95. Aggarwal R, Charles-Schoeman C, Schessl J. PMID: 36599070.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD Open. 2022 11; 8(2). Weitz JI, Szekanecz Z, Charles-Schoeman C, Vranic I, Sahin B, Paciga SA, Wang Z, Hyde C, Martin DA. PMID: 36323490; PMCID: PMC9639150.
      View in: PubMed   Mentions: 5  Translation:Humans
    17. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022 10 06; 387(14):1264-1278. Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgo Z, Dimachkie MM, Griger Z, Moiseev S, Oddis C, Schiopu E, Vencovský J, Beckmann I, Clodi E, Bugrova O, Dankó K, Ernste F, Goyal NA, Heuer M, Hudson M, Hussain YM, Karam C, Magnolo N, Nelson R, Pozur N, Prystupa L, Sárdy M, Valenzuela G, van der Kooi AJ, Vu T, Worm M, Levine T, ProDERM Trial Group. PMID: 36198179.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    18. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023 01; 82(1):119-129. Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. PMID: 36137735; PMCID: PMC9811099.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    19. Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis. Clin Rheumatol. 2023 Jan; 42(1):75-82. Razmjou AA, Wang JM, Shahbazian A, Reddy S, Charles-Schoeman C. PMID: 36138190; PMCID: PMC9823017.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. Arthritis Res Ther. 2022 08 25; 24(1):207. Rubbert-Roth A, Furst DE, Fiore S, Praestgaard A, Bykerk V, Bingham CO, Charles-Schoeman C, Burmester G. PMID: 36008838; PMCID: PMC9404615.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    21. Abnormal paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2022 05 30; 61(6):2512-2523. Bae SS, Shahbazian A, Wang J, Golub I, Oganesian B, Dowd T, Vayngortin B, Wang R, Elashoff D, Reddy ST, Charles-Schoeman C. PMID: 34698804; PMCID: PMC9308379.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Altered Gut Microbiome in Patients With Dermatomyositis. ACR Open Rheumatol. 2022 Aug; 4(8):658-670. Bae SS, Dong TS, Wang J, Lagishetty V, Katzka W, Jacobs JP, Charles-Schoeman C. PMID: 35615912; PMCID: PMC9374048.
      View in: PubMed   Mentions: 1  
    23. Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. Arthritis Care Res (Hoboken). 2021 04; 73(4):471-480. Curtis JR, Weinblatt M, Saag K, Bykerk VP, Furst DE, Fiore S, St John G, Kimura T, Zheng S, Bingham CO, Wright G, Bergman M, Nola K, Charles-Schoeman C, Shadick N. PMID: 33002337; PMCID: PMC8048846.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    24. A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus. ACR Open Rheumatol. 2021 Apr; 3(4):209-220. Skaggs BJ, Grossman J, Sahakian L, Perry L, FitzGerald J, Charles-Schoeman C, Gorn A, Taylor M, Moriarty J, Ragavendra N, Weisman M, Wallace DJ, Hahn BH, McMahon M. PMID: 33605563; PMCID: PMC8063147.
      View in: PubMed   Mentions: 12  
    25. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study"). Medicine (Baltimore). 2021 Jan 08; 100(1):e23677. Aggarwal R, Charles-Schoeman C, Schessl J, Dimachkie MM, Beckmann I, Levine T. PMID: 33429735; PMCID: PMC7793357.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    26. High- density lipoprotein function is abnormal in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2020 11 01; 59(11):3515-3525. Bae SS, Lee YY, Shahbazian A, Wang J, Meriwether D, Golub I, Oganesian B, Dowd T, Reddy ST, Charles-Schoeman C. PMID: 32830270; PMCID: PMC7590404.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    27. Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice. Sci Rep. 2020 10 08; 10(1):16848. Charles-Schoeman C, Wang J, Shahbazian A, Lee YY, Wang X, Grijalva V, Brahn E, Shih DM, Devarajan A, Montano C, Lusis AJ, Reddy ST. PMID: 33033318; PMCID: PMC7546628.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    28. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 10; 6(3). Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. PMID: 33127856; PMCID: PMC7722371.
      View in: PubMed   Mentions: 51  Translation:HumansCTClinical Trials
    29. Major Lipids and Future Risk of Pneumonia: 20-Year Observation of the Atherosclerosis Risk in Communities (ARIC) Study Cohort. Am J Med. 2021 02; 134(2):243-251.e2. Bae SS, Chang LC, Merkin SS, Elashoff D, Ishigami J, Matsushita K, Charles-Schoeman C. PMID: 32814017; PMCID: PMC7870521.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020 11; 79(11):1400-1413. Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, Kremer J, Greenberg J, Malley W, Onofrei A, Kanik KS, Graham D, Wang C, Connell C, Valdez H, Hauben M, Hung E, Madsen A, Jones TV, Curtis JR. PMID: 32759265; PMCID: PMC7569391.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    31. Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: A retrospective study. Clin Cardiol. 2020 Jul; 43(7):732-742. Bae SS, Oganesian B, Golub I, Charles-Schoeman C. PMID: 32432360; PMCID: PMC7368310.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    32. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. Arthritis Care Res (Hoboken). 2019 10; 71(10):1387-1395. Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R. PMID: 31112005; PMCID: PMC6764856.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    33. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019 09; 71(9):1450-1459. Charles-Schoeman C, DeMasi R, Valdez H, Soma K, Hwang LJ, Boy MG, Biswas P, McInnes IB. PMID: 31385441; PMCID: PMC6754249.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    34. Dr. Charles-Schoeman and E. Bananis Reply. J Rheumatol. 2018 11; 45(11):1605. Charles-Schoeman C, Bananis E. PMID: 30385698.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study. Clin Rheumatol. 2018 Aug; 37(8):2113-2123. Bae S, Charles-Schoeman C. PMID: 29971584.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    36. Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis. Atherosclerosis. 2018 08; 275:107-114. Charles-Schoeman C, Gugiu GB, Ge H, Shahbazian A, Lee YY, Wang X, Furst DE, Ranganath VK, Maldonado M, Lee T, Reddy ST. PMID: 29886354; PMCID: PMC6113060.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    37. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. J Rheumatol. 2018 02; 45(2):177-187. Charles-Schoeman C, van der Heijde D, Burmester GR, Nash P, Zerbini CAF, Connell CA, Fan H, Kwok K, Bananis E, Fleischmann R. PMID: 29142036.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    38. High levels of oxidized fatty acids in HDL are associated with impaired HDL function in patients with active rheumatoid arthritis. Clin Rheumatol. 2018 Mar; 37(3):615-622. Charles-Schoeman C, Meriwether D, Lee YY, Shahbazian A, Reddy ST. PMID: 29129008; PMCID: PMC6148336.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    39. Cardiac Transplantation in Dermatomyositis: A case report and literature review. Hum Pathol (N Y). 2017 Jun; 8:55-58. Bae S, Khanlou N, Charles-Schoeman C. PMID: 29204355; PMCID: PMC5710758.
      View in: PubMed   Mentions: 3  
    40. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul; 76(7):1253-1262. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. PMID: 28143815; PMCID: PMC5530353.
      View in: PubMed   Mentions: 146     Fields:    Translation:Humans
    41. Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. Arthritis Rheumatol. 2017 01; 69(1):46-57. Charles-Schoeman C, Yin Lee Y, Shahbazian A, Wang X, Elashoff D, Curtis JR, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, Paulus H, O'Dell J, Bathon J, Louis Bridges S, Reddy ST. PMID: 27483410; PMCID: PMC5195879.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    42. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016 12; 46(3):261-271. Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, Boy M, Zuckerman A, Soma K, Geier J, Kwok K, Riese R. PMID: 27443588.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    43. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016 08; 46(1):71-80. Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, Zuckerman A, Riese R. PMID: 27079757.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    44. Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheumatol. 2016 Mar; 68(3):577-86. Charles-Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, O'Dell J, Bathon JM, Paulus H, Bridges SL, Curtis JR. PMID: 26606398; PMCID: PMC4774543.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    45. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016 07; 75(7):1293-301. Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, Hendrikx T, Bananis E, Fleischmann R. PMID: 26275429; PMCID: PMC4941182.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    46. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015 03; 67(3):616-25. Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, Riese R, Zuckerman A, McInnes IB. PMID: 25470338; PMCID: PMC5024065.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    47. The heart in inflammatory myopathies. Rheum Dis Clin North Am. 2014 Feb; 40(1):1-10. Van Gelder H, Charles-Schoeman C. PMID: 24268006.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    48. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol. 2014 Jan; 66(1):130-9. McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, Weisman MH, Wallace DJ, Hahn BH. PMID: 24449580; PMCID: PMC4106468.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    49. Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum. 2013 Nov; 65(11):2765-72. Charles-Schoeman C, Lee YY, Shahbazian A, Gorn AH, Fitzgerald J, Ranganath VK, Taylor M, Ragavendra N, McMahon M, Elashoff D, Reddy ST. PMID: 23917967; PMCID: PMC4410876.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    50. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013 Jun; 65(6):1430-8. Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL, Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR. PMID: 23460074; PMCID: PMC3672346.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    51. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013 Feb 09; 381(9865):451-60. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C, ORAL Step investigators. PMID: 23294500.
      View in: PubMed   Mentions: 284     Fields:    Translation:HumansCTClinical Trials
    52. Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep. 2012 Oct; 14(5):455-62. Charles-Schoeman C. PMID: 22791398; PMCID: PMC3436948.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    53. Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey. Clin Rheumatol. 2012 Aug; 31(8):1163-8. Charles-Schoeman C, Amjadi SS, Paulus HE, International Myositis Assessment and Clinical Studies Group. PMID: 22526479.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    54. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012 Jul; 71(7):1157-62. Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST. PMID: 22267330; PMCID: PMC3428121.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansAnimalsCells
    55. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 2012 Jun; 64(6):1828-37. Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, Lee TD, Reddy ST. PMID: 22231638; PMCID: PMC3330163.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    56. Nicotinamide adenine dinucleotide tetrazolium reductase identifies microvasculature activation in muscle from adult patients with dermatomyositis. J Rheumatol. 2012 Jan; 39(1):94-9. Charles-Schoeman C, Verity MA. PMID: 22174214.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    57. A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res. 2011 Dec; 52(12):2341-2351. Kelesidis T, Currier JS, Huynh D, Meriwether D, Charles-Schoeman C, Reddy ST, Fogelman AM, Navab M, Yang OO. PMID: 21957198; PMCID: PMC3220300.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    58. An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy. Rheumatol Int. 2012 Sep; 32(9):2725-9. Kovalchik SA, Charles-Schoeman C, Khanna D, Paulus HE. PMID: 21805175.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    59. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis. 2011 Sep; 70(9):1619-24. McMahon M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH. PMID: 21670088; PMCID: PMC3147230.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    60. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ J. 2011; 75(7):1533-8. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, Kwon M, Ganapathy E, Meriwether D, Farias-Eisner R, Fogelman AM, Reddy ST. PMID: 21628835; PMCID: PMC3625624.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    61. Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Feb; 62(2):258-65. Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH, McMahon M. PMID: 20191526; PMCID: PMC2853476.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    62. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 2009 Oct; 60(10):2870-9. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, Park G, McMahon M, Paulus HE, Fogelman AM, Reddy ST. PMID: 19790070; PMCID: PMC2828490.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    63. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 2009 Aug; 60(8):2428-37. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH. PMID: 19644959; PMCID: PMC2753974.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    64. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol. 2008 May; 127(2):234-44. Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, Wagner AC, Fogelman AM, Brahn E. PMID: 18337176.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    65. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol. 2007 Jul; 34(7):1459-64. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ. PMID: 17552046.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Christina's Networks
    Concepts (251)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (33)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California